Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2026 07:13 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July...
July 21, 2026 07:00 ET | Source: PharmAla Biotech

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

PharmAla signs definitive agreement with Jupiter Neurosciences to out-license their patented ALA-002 molecule, securing up-front and development payments.
July 06, 2026 08:15 ET | Source: PharmAla Biotech

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

PharmAla announces the completion of manufacture of ALA-002 drug substance, as well as a full operational update on the LaNeo Gen 2 patented drug family.
May 27, 2026 07:30 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease

Investigational Oral Candidate JOTROL™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter...
May 20, 2026 08:15 ET | Source: PharmAla Biotech

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
May 20, 2026 07:38 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May ...
May 13, 2026 08:30 ET | Source: PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla announces signed definitive agreement to form a special purpose vehicle to spin out APA-01 entity for development, partnering with Diteba
April 27, 2026 08:00 ET | Source: PharmAla Biotech

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla signs a binding letter of intent to spin out its APA-01 novel asset into a joint venture with Aluvaris and Diteba, with deal to close in June.
April 21, 2026 16:05 ET | Source: PharmAla Biotech

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla files Q2 quarterly financials with increased customer deposits.
April 20, 2026 08:15 ET | Source: PharmAla Biotech

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.